Celldex Therapeutics, Inc. (CLDX): Product News News

CLDX – Reports that the randomized Phase 2b METRIC Study of glembatumumab vedotin compared to Xeloda in patients with metastatic triple-negative breast cancers that overexpress gpNMB failed to meet its primary endpoint.


Key Facts Surrounding This News Item


  • CLDX had a POWR Rating of D (Sell) coming into today.
  • CLDX was 1.32% above its 10-Day Moving Average coming into today.
  • CLDX was -4.72% below its 20-Day Moving Average coming into today.
  • CLDX was -9.64% below its 50-Day Moving Average coming into today.
  • CLDX was -18.39% below its 100-Day Moving Average coming into today.
  • CLDX was -17.89% below its 200-Day Moving Average coming into today.
  • CLDX had returned -24.30% year-to-date leading up to today’s news, versus a -0.24% return from the benchmark S&P 500 during the same period.

More Info About Celldex Therapeutics, Inc. (CLDX)


Celldex Therapeutics is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The company was founded in 2004 and is based in Hampton, New Jersey. View our full CLDX ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

CLDX at a Glance

CLDX Current POWR Rating™
Overall POWR Rating™
CLDX Current Price $0.68 6.97%
More CLDX Ratings, Data, and News

CLDX Price Reaction

The day of this event (Apr. 16, 2018)
CLDX Closing Price$0.76 64.65%
CLDX Volume29,243,200
1,877.29% from avg
Leading up to this event
CLDX 1-mo return12.96%
After this event
CLDX 1-day return172.15%
CLDX 3-day return216.60%

CLDX Price Chart



More Celldex Therapeutics, Inc. (CLDX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CLDX News
Page generated in 1.0426 seconds.